@article {44702,
	title = {28S rRNA-Derived Fragments Represent an Independent Molecular Predictor of Short-Term Relapse in Prostate Cancer},
	journal = {Int J Mol Sci},
	volume = {25},
	number = {1},
	year = {2023},
	note = {Diamantopoulos, Marios AGeorgoulia, Konstantina KLevis, PanagiotisKotronopoulos, GeorgiosStravodimos, KonstantinosKontos, Christos KAvgeris, MargaritisScorilas, AndreasengSwitzerland2024/01/11 07:42Int J Mol Sci. 2023 Dec 23;25(1):239. doi: 10.3390/ijms25010239.},
	month = {Dec 23},
	abstract = {Prostate cancer (PCa) is a global health concern, being a leading cause of cancer-related mortality among males. Early detection and accurate prognosis are crucial for effective management. This study delves into the diagnostic and prognostic potential of 28S rRNA-derived fragments (rRFs) in PCa. Total RNA extracted from 89 PCa and 53 benign prostate hyperplasia (BPH) tissue specimens. After 3{\textquoteright}-end polyadenylation, we performed reverse transcription to create first-strand cDNA. Using an in-house quantitative real-time PCR (qPCR) assay, we quantified 28S rRF levels. Post-treatment biochemical relapse served as the clinical endpoint event for survival analysis, which we validated internally through bootstrap analysis. Our results revealed downregulated 28S rRF levels in PCa compared to BPH patients. Additionally, we observed a significant positive correlation between 28S rRF levels and higher Gleason scores and tumor stages. Furthermore, PCa patients with elevated 28S rRF expression had a significantly higher risk of post-treatment disease relapse independently of clinicopathological data. In conclusion, our study demonstrates, for the first time, the prognostic value of 28S rRF in prostate adenocarcinoma. Elevated 28S rRF levels independently predict short-term PCa relapse and enhance risk stratification. This establishes 28S rRF as a potential novel molecular marker for PCa prognosis.},
	keywords = {*Prostatic Hyperplasia/genetics, *Prostatic Neoplasms/genetics, Biological Assay, cancer biomarker, Chronic Disease, clinical significance, design of the study, Humans, in the collection, analyses, or interpretation of the data, in the writing of the manuscript, Male, or in the decision to publish the results., prostate tumor, RNA, Ribosomal, 28S, rRFs},
	isbn = {1422-0067 (Electronic)1422-0067 (Linking)},
	author = {Diamantopoulos, M.A. and Georgoulia, K. K. and Levis, P. and Kotronopoulos, G. and Stravodimos, K. and Kontos, C.K. and Avgeris, M. and Scorilas, A.}
}
